Summary
In situ determination of proliferative activity was performed on 184 consecutive primary invasive breast cancers. Methods used were monoclonal antibody Ki-67 in immunohistochemistry and thymidine labeling index. Tumor proliferation correlated between both methods (p = 0.0001). For thymidine labeling index and Ki-67, respectively, significant correlations existed with histologic tumour grade and steroid hormone receptors (Tumor grade: TLIp = 0.0001; Ki-67 p = 0.0001. ER-ICA: TLI = 0.0001; Ki-67 p = 0.014. PgR-ICA: TLIp = 0.0001; Ki-67 p = 0.0008).
For thymidine labeling index a significant correlation was demonstrated for overall survival (p = 0.001) and recurrence free survival (p = 0.01). No statistical significance was observed for clinical outcome and Ki-67 (overall survival p = 0.18; recurrence free survival p = 0.1). None of the factors, TLI or Ki-67, was an independent prognostic factor as demonstrated by multivariate analysis.
Article PDF
Avoid common mistakes on your manuscript.
References
Carter C, Allen C, Henson DE: Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 63: 181–187, 1989
Bloom HJG, Richardson WW: Histologic grading and prognosis in breast cancer. A study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11: 359–377, 1957
Le Doussal V, Tubiana-Hulin M, Friedman S, Hacene K, Spyratos F, Brunet M: Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). Cancer 64: 1914–1921, 1989
Knight WA III, Livingston BB, Gregory EJ, McGuire WL: Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res 37: 4667–4671, 1977
Kinsel LB, Szabo E, Greene GL, Konrath J, Leight GS, McCarty KS Jr: Immunocytochemical analysis of estrogen receptors as a predictor of prognosis in breast cancer patients: comparison with qualitative biochemical methods. Cancer Res 49: 1052–1056, 1989
Reiner A, Neumeister B, Spona J, Reiner G, Schemper M, Jakesz R: Immunocytochemical localization of estrogen and progesterone receptor and prognosis in human primary breast cancer. Cancer Res 50: 7057–7061, 1990
Baak JPA, Kurver PHJ, De Snoo-Niewlaat AJE, De Graef S, Makkink B, Boon M: Prognostic indicators in breast cancer- morphometric methods. Histopathology 6: 327–339, 1982
Fisher B, Gunduz N, Costantino J, Fisher E, Redmond C, Mamounas EP, Siderits R: DNA flow cytometric analysis of primary operable breast cancer. Cancer 68: 1465–1475, 1991
McGuire WL, Dressler LG: Emerging impact of flow cytometry in predicting recurrence and survival in breast cancer patients. JNCI 75: 405–410, 1985
Meyer JS, McDivitt RW: Reliability and stability of the thymidine labeling index of breast carcinoma. Lab Invest 54: 160–164, 1986
Meyer JS, Connor RE:In vitro labeling of solid tissues with tritiated thymidine for autoradiographic detection of S-phase nuclei. Stain Technol 52: 185–195, 1977
Gerdes J, Schwab U, Lemke H, Stein H: Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 31: 13–20, 1983
Gerdes J, Pickartz H, Brotherton J, Hammerstein J, Weitzel H, Stein H: Growth fractions and estrogen receptors in human breast cancers as determinedin situ with monoclonal antibodies. Am J Pathol 129: 486–492, 1987
Meyer JS, Province M: Proliferation index of breast carcinoma by thymidine labeling: prognostic power independent of stage, estrogen and progesterone receptors. Breast Cancer Res Treat 12: 191, 1988
Gerdes J, Lelle RJ, Pickartz H, Heidenreich W, Schwarting R, Kurtsiefer L, Stauch G, Stein H: Growth fraction in breast cancer determinedin situ with monoclonal antibody Ki-67. J Clin Pathol 39: 977–980, 1986
Wrba F, Chott A, Reiner A, Reiner G, Markis-Ritzinger E, Holzner JH: Ki-67 immunoreactivity in breast carcinomas in relation to transferrin receptor expression, estrogen receptor status and morphological criteria. Oncology 46: 255–259, 1989
Wintzer HO, Zipfel I, Schulte-Möntig J, Hellerich U, v. Kleist S: Ki-67 immunostaining in human breast tumors and its relationship to prognosis. Cancer 67: 421–428, 1991
Silvestrini R, Daidone MG, Di Fronzo G: Relationship between proliferative activity and estrogen receptors in breast cancer. Cancer 44: 665–670, 1979
Meyer JS, Hixon B: Advanced stage and early relapse of breast carcinomas associated with high thymidine labeling indices. Cancer Res 39: 4042–4047, 1979
Tubiana M, Pejovic MH, Renaud A: Kinetic parameters and the course of disease in breast cancer. Cancer 47: 937–943, 1981
Meyer JS, Friedman E, McCrate MM, Bauer WC: Prediction of early course of breast carcinomas by thymidine labeling. Cancer 51: 1879–1886, 1983
Silvestrini R, Daidone MG, DiFronzo Get al.: Prognostic implication of labeling index versus estrogen receptors and tumor size in node-negative breast cancer. Breast Cancer Res Treat 7: 161–169, 1986
Tubiana M, Pejovic MH, Koscielny S, Chavaudra N, Malaise E: Growth rate, kinetics of tumor cell proliferation and long term outcome in human breast cancer. Int J Cancer 44: 17, 1989
Stauch G, Lelle RJ, Broermann L, Georgii A: Comparison of prognostic factors in breast carcinoma: Grading of malignancy according to Bloom and Richardson versus determination of Ki-67 growth fraction. Verh Dtsch Ges Path 72: 256–259, 1988
Weikel W, Beck T, Mitze M, Knapstein PG: Immunohistochemical evaluation of growth fractions in human breast cancer using monoclonal antibody Ki-67. Breast Cancer Res Treat 18: 149–154, 1991
Azzopardi JG: Problems in breast pathology. In: Major problems in pathology, Vol 11. WB Saunders, Philadelphia, 1979, 240–257
Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481, 1958
Breslow N: A generalized Kruskal-Wallis test for comparing k samples subject to unequal censorship. Biometrika 57: 579–594, 1970
Cox DR: Regression models and life tables (with discussion). J Roy Stat Soc 34 B: 187–220, 1972
Kendall M, Gibbons JD: Rank Correlation Methods. 5 Edition, Edward Arnold, 1990
Gnant M, Seifert M, Jakesz R, Adler A, Mittlboeck M, Sevelda P: Breast cancer and timing of surgery during menstrual cycle. A 5-year analysis of 385 pre-menopausal women. Int J Cancer 52: 707–712, 1992
Jakesz R, Hausmaninger H, Depisch Det al.: Austrian Cooperative Breast Cancer Study Group - Update on already closed and current protocols in patients with operable breast cancer. Acta Chir Austriaca 2: 63–69, 1991
Gnant M, Blijham G, Reiner A, Reiner G, Reynders M, Schutte B, van Asche C, Steger G, Jakesz R: DNA ploidy and other results of DNA flow cytometry as prognostic factors in operable breast cancer. Europ J Cancer 23: 711–716, 1992
Gnant M, Blijham G, Schemper M, Reiner G, Reiner A, Spona S, Reynders M, Schutte B, van Asche C, Steger G, Jakesz R: The prognostic significance of DNA flow cytometry in human breast cancer - 10 year results of a randomised study. Acta Chir Austriaca 2: 43–48, 1991
Kamel OW, Franklin WA, Ringus JC, Meyer JS: Thymidine labeling index and Ki-67 growth fraction in lesions of the breast. Am J Path 134(1): 107–113, 1989
Meyer JS, Bauer WC, Stevens SC, Rao BR, White WL: S-phase fractions of breast carcinomas. Relationships to morphology, estrogen and progesterone-receptors, and early recurrence. Bull Cancer 65: 449–454, 1978
Charpin C, Andrac L, Vacheret H, Habib MC, Devictor B, Lavant MN, Toga M: Multiparametric evaluation (SAMBA) of growth fraction (monoclonal Ki-67) in breast carcinoma tissue sections. Cancer Res 48: 4368–4374, 1988
Isola JJ, Helin HJ, Helle MJ, Kallioniemi OP: Evaluation of cell proliferation in breast carcinoma. Comparison of Ki-67 immunochemistry study, DNA flow cytometric analysis, and mitotic count. Cancer 65: 1180–1184, 1990
Silvestrini R: Feasibility and reproducibility of the [3H]-thymidine labeling index in breast cancer. Cell Prol 24: 437–445, 1991
Veronese SM, Gambacorta M: Detection of Ki-67 proliferation ratio in breast cancer. Am J Clin Path 95: 30–34, 1991
Helin ML, Helle MJ, Helin HJ, Isola JJ: Proliferative activity and steroid receptors determined by immunochemistry in adjacent frozen sections of 102 breast carcinomas. Arch Pathol Lab Med 113: 845–857, 1989
Meyer JS, Bauer WC, Ramanath R: Subpopulations of breast carcinoma defined by S-phase fraction, morphology, and estrogen receptor content. Lab Invest 39: 225–235, 1978
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rudas, M., Gnant, M.F.X., Mittlböck, M. et al. Thymidine labeling index and Ki-67 growth fraction in breast cancer: Comparison and correlation with prognosis. Breast Cancer Res Tr 32, 165–175 (1994). https://doi.org/10.1007/BF00665767
Issue Date:
DOI: https://doi.org/10.1007/BF00665767